PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial-Reference-Cited by-同舟云学术

PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial

Published:2024-03 Issue:3 Volume:12 Page:174-183
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Koren Michael J,Descamps Olivier,Hata Yoshiki,Hengeveld Ellen Margo,Hovingh G Kees,Ikonomidis Ignatios,Radu Juul Jensen Maria D,Langbakke Irene Hedelund,Martens Fabrice M A C,Søndergaard Anette Luther,Witkowski Adam,Koenig Wolfgang

Funder

Novo Nordisk

Publisher

Elsevier BV

Reference24 articles.

1. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study;Koren;Lancet,2012

2. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial;Raal;Lancet,2015

3. Targeting PCSK9 inhibitors to those who will benefit most;Turner;Lancet Diabetes Endocrinol,2022

4. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease;O'Donoghue;Circulation,2022

5. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in risk stratification and management strategies in primary cardiovascular prevention;Atherosclerosis;2024-08

2. The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias;Journal of Clinical Medicine;2024-07-16

3. Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future;Current Problems in Cardiology;2024-07

4. Oral PCSK9 Inhibitors;Current Atherosclerosis Reports;2024-03-27

5. An anti-PCSK9 pill a day to keep cholesterol away: next steps?;The Lancet Diabetes & Endocrinology;2024-03